Canada markets close in 2 hours 19 minutes

Metagenomi, Inc. (MGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.79-0.10 (-1.45%)
As of 01:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close6.89
Bid6.74 x 100
Ask6.87 x 100
Day's Range6.66 - 7.05
52 Week Range6.50 - 12.74
Avg. Volume224,179
Market Cap254.438M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
  • GlobeNewswire

    Metagenomi to Present at Upcoming Scientific Meetings

    - Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will prese

  • GlobeNewswire

    Metagenomi Reports Business Updates and Full Year 2023 Financial Results

    Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability demonstrated with CRISPR-associated transposase (CAST) system being developed to enable >10,000 base pair, targeted genomic integrations Ultra-small base editing systems (SMART) are the smallest nickase-based systems characterized to-date, designed to enable more efficient delivery via si

  • GlobeNewswire

    Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference

    EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived gene edit­ing tool­box, today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the 44th Annual Cowen Healthcare Conference on Wednesday, March 6, 2024 from